Optimization of Tyrosine Kinase Inhibitor-Loaded Gold Nanoparticles for Stimuli-Triggered Antileukemic Drug Release
Source abstract
Abstract
Tyrosine kinase inhibitor (TKI) therapy is gaining attraction in advanced cancer therapeutics due to the ubiquity of kinases in cell survival and differentiation. Great progress was made in the past years in identifying tyrosine kinases that can function as valuable molecular targets and for the entrapment of their corresponding inhibitors in delivery compounds for triggered release. Herein we present a class of drug-delivery nanocompounds based on TKI Midostaurin-loaded gold nanoparticles that have the potential to be used as theranostic agents for the targeting of the FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia. We optimized the nanocompounds’ formulation with loading efficiency in the 84–94% range and studied the drug release behavior in the presence of stimuli-responsive polymers. The therapeutic activity of MDS-loaded particles, superior to that of the free drug, was confirmed with toxicities depending on specific dosage ranges. No effect was observed on FLT3-negative cells or for the unloaded particles. Beyond druggability, we can track this type of nanocarrier inside biological structures as demonstrated via dark field microscopy. These properties might contribute to the facilitation of personalized drug dosage administration, critical for attaining a maximal therapeutic effect.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques · Acute Myeloid Leukemia Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Interdisciplinary Research Institute in Bio-Nano-Sciences, Babes-Bolyai University, 400271 Cluj-Napoca, Romania
National Institute for Research and Development of Isotopic and Molecular Technologies, 400293 Cluj-Napoca, Romania
Research Center for Advanced Medicine—MEDFUTURE, Department of Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Romania
Department of Hematology, Oncologic Institute Prof. Dr. Ion Chiricuta, 400015 Cluj-Napoca, Romania
Funding
CNCS-UEFISCDI
References (59)
Show source-provided references
1. Incidence, survival and prevalence of myeloid malignancies in Europe10.1016/j.ejca.2012.05.024 ↗
2. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet10.1182/blood-2009-07-235358 ↗
3. (2021, September 14). Key Statistics for Acute Myeloid Leukemia (AML)’. Available online: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html.
4. Leukemia incidence trends at the global, regional, and national level between 1990 and 201710.1186/s40164-020-00170-6 ↗
5. Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy10.2147/IJN.S94064 ↗
6. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?10.1016/j.blre.2020.100675 ↗
7. The kinome ‘at large’ in cancer10.1038/nrc.2015.18 ↗
8. Kinase-targeted cancer therapies: Progress, challenges and future directions10.1186/s12943-018-0804-2 ↗
9. Fernandez, S., Desplat, V., Villacreces, A., Guitart, A.V., Milpied, N., Pigneux, A., Vigon, I., Pasquet, J.-M., and Dumas, P.-Y. (2019). Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?. Int. J. Mol. Sci., 20.10.3390/ijms20143429 ↗
10. Flt3 mutations and leukaemia10.1046/j.1365-2141.2003.04500.x ↗
11. Targeting FLT3 mutations in AML: Review of current knowledge and evidence10.1038/s41375-018-0357-9 ↗
12. Design of FLT3 Inhibitor—Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia10.1186/s11671-015-1154-2 ↗
13. FLT3 inhibitors in acute myeloid leukemia10.1186/s13045-018-0675-4 ↗
14. Midostaurin approved for FLT3-mutated AML10.1182/blood-2017-05-782292 ↗
15. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia10.1038/leu.2012.115 ↗
16. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation10.1056/NEJMoa1614359 ↗
17. Nanomedicines for the treatment of hematological malignancies10.1016/j.jconrel.2018.08.034 ↗
18. Applications of Nanoparticles for Anticancer Drug Delivery: A Review10.1166/jnn.2015.10298 ↗
19. Physical-, chemical-, and biological-responsive nanomedicine for cancer therapy10.1002/wnan.1581 ↗
20. Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy10.3389/fbioe.2018.00110 ↗
21. Polyethylene Glycol-Mediated Synthesis of Cubic Iron Oxide Nanoparticles with High Heating Power10.1186/s11671-015-1091-0 ↗
22. CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia10.1016/j.colsurfb.2019.110478 ↗
23. Antibody Conjugated, Raman Tagged Hollow Gold–Silver Nanospheres for Specific Targeting and Multimodal Dark-Field/SERS/Two Photon-FLIM Imaging of CD19(+) B Lymphoblasts10.1021/acsami.7b05145 ↗
24. Recent progress in theranostic applications of hybrid gold nanoparticles10.1016/j.ejmech.2017.06.034 ↗
25. Classification of stimuli–responsive polymers as anticancer drug delivery systems10.3109/10717544.2014.887157 ↗
26. Epirubicin-loaded marine carrageenan oligosaccharide capped gold nanoparticle system for pH-triggered anticancer drug release10.1038/s41598-019-43106-9 ↗
27. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel10.1016/j.ijpharm.2011.01.061 ↗
28. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro10.1016/j.ijpharm.2011.10.029 ↗
29. Bioactive Lipids-Based pH Sensitive Micelles for Co-Delivery of Doxorubicin and Ceramide to Overcome Multidrug Resistance in Leukemia10.1007/s11095-013-1121-5 ↗
30. pH-responsive unimolecular micelle-gold nanoparticles-drug nanohybrid system for cancer theranostics10.1016/j.actbio.2017.06.003 ↗
31. Smart pH-sensitive micelles based on redox degradable polymers as DOX/GNPs carriers for controlled drug release and CT imaging10.1016/j.colsurfb.2017.12.008 ↗
32. Peptide-assembled hydrogels for pH-controllable drug release10.1016/j.colsurfb.2019.110567 ↗
33. pH-Sensitive Nano-Complexes Overcome Drug Resistance and Inhibit Metastasis of Breast Cancer by Silencing Akt Expression10.7150/thno.21516 ↗
34. Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment10.1021/acs.langmuir.7b01072 ↗
35. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides10.1186/s12951-019-0519-6 ↗
36. Diosgenin-conjugated PCL–MPEG polymeric nanoparticles for the co-delivery of anticancer drugs: Design, optimization, in vitro drug release and evaluation of anticancer activity10.1039/C9NJ00659A ↗
37. Sustained anti-BCR-ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells10.1039/C4MD00348A ↗
38. Cortese, B., D’amone, S., and Palamà, I.E. (2018). Wool-Like Hollow Polymeric Nanoparticles for CML Chemo-Combinatorial Therapy. Pharmaceutics, 10.10.3390/pharmaceutics10020052 ↗
39. Gelatin Coated Gold Nanoparticles as Carriers of FLT3 Inhibitors for Acute Myeloid Leukemia Treatment10.1111/cbdd.12725 ↗
40. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain10.1038/sj.onc.1205332 ↗
41. Analysis of Chromosomal Aberrations and FLT3 gene Mutations in Childhood Acute Myelogenous Leukemia Patients10.5505/tjh.2012.24392 ↗
42. A study of the nucleation and growth processes in the synthesis of colloidal gold10.1039/df9511100055 ↗
43. Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions10.1038/physci241020a0 ↗
44. Investigation of pseudo-polyanion formation between polyvinylpyrrolidone and sodium dodecanoate in aqueous solution by capillary electrophoresis, conductometry, tensiometry and calcium stability10.1039/C6RA26629K ↗
45. Understanding the Role of Poly(vinylpyrrolidone) in Stabilizing and Capping Colloidal Silver Nanocrystals10.1021/acsnano.1c01668 ↗
46. Focused Ultrasound–Triggered Release of Tyrosine Kinase Inhibitor From Thermosensitive Liposomes for Treatment of Renal Cell Carcinoma10.1016/j.xphs.2017.01.027 ↗
47. LED-activated methylene blue-loaded Pluronic-nanogold hybrids for in vitro photodynamic therapy: Methylene blue-nanogold hybrids for LED induced PDT10.1002/jbio.201300058 ↗
48. Hyperspectral enhanced dark field microscopy for imaging blood cells10.1002/jbio.201300067 ↗
49. The role of FLT3 in haematopoietic malignancies10.1038/nrc1169 ↗
50. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: Biology and therapeutic implications10.1186/1756-8722-4-13 ↗
51. Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells10.1002/ajh.20520 ↗
52. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines10.1038/sj.onc.1203354 ↗
53. Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT510.1016/j.bbrc.2004.02.018 ↗
54. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML10.1182/blood-2007-05-092510 ↗
55. Midostaurin: An emerging treatment for acute myeloid leukemia patients10.2147/JBM.S100283 ↗
56. Emerging therapies for acute myeloid leukemia10.1186/s13045-017-0463-6 ↗
57. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: Design, development, and potential place in therapy10.2147/OTT.S127679 ↗
58. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: The induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases10.1182/blood-2006-04-015487 ↗
59. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia10.1038/leu.2012.114 ↗